Eliem Therapeutics could be in trouble following the announcement that its drug candidate ETX-810, intended to treat diabetic peripheral neuropathic pain, did not meet its primary endpoint.
Octant announced an $80 million Series B financing round, a Deep Mutual Scanning (DMS) biopharma partnership with Bristol Myers Squibb and key appointments to its leadership.
Orasis Pharmaceuticals announced that its eye drop candidate CSF-1 met all primary and key secondary endpoints in Phase III clinical trials. CSF-1 is intended to treat presbyopia.
Proposing a standardized definition of what disease modification looks like in SLE and LN that can drive outcomes measured in clinical trials, is an important step.
Arcturus Therapeutics announced positive Phase III trial results for its mRNA vaccine candidate, ARCT-154, intended to prevent COVID-19 caused by the SARS-CoV-2 virus.
INmune Bio has announced that it has dosed the first patient in its Phase II clinical trial of XPro1595 for the treatment of neuroinflammation as a cause of Alzheimer’s Disease.
Regeneron announced it has acquired Checkmate Pharmaceuticals and that it has entered a clinical trial collaboration with SpringWorks Therapeutics to treat multiple myeloma.
Heat Biologics announced a new development underway in its partnership with Scorpion Biological Services to develop a manufacturing facility in Manhattan, Kansas.
In honor of World Hemophilia Day, BioSpace takes a look at some of the facts relating to the disease, and some of the highlights in recent hemophilia research and development.
Scientists recently announced the complete sequencing of the entire human genome. Biotech company PacBio - and HiFi sequencing - played a big role in this milestone.
McKinsey & Company is under fire for allegedly allowing its employees to work simultaneously for big pharma companies and serve as consultants for the U.S. Food and Drug Administration.
The revised operating plan also includes reductions in spending related to general and administrative expenses and investments in its research platform.
